Financial Survey: Mateon Therapeutics (OTCMKTS:MATN) vs. Rapport Therapeutics (NASDAQ:RAPP)

Mateon Therapeutics (OTCMKTS:MATN) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Profitability

This table compares Mateon Therapeutics and Rapport Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mateon Therapeutics	N/A	-64.66%	-42.92%
Rapport Therapeutics	N/A	N/A	N/A

Insider & Institutional Ownership

0.1% of Mateon Therapeutics shares are held by institutional investors. 39.2% of Mateon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Mateon Therapeutics and Rapport Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mateon Therapeutics	0	0	0	0	0.00
Rapport Therapeutics	0	0	3	0	3.00

Rapport Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 45.83%. Given Rapport Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Rapport Therapeutics is more favorable than Mateon Therapeutics.

Earnings & Valuation

This table compares Mateon Therapeutics and Rapport Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mateon Therapeutics	N/A	N/A	-$6.64 million	N/A	N/A
Rapport Therapeutics	N/A	N/A	-$34.79 million	N/A	N/A

Summary

Rapport Therapeutics beats Mateon Therapeutics on 5 of the 8 factors compared between the two stocks.

About Mateon Therapeutics

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.